Table 3.
Characteristics | All MIS-C | Wuhan period | Alpha period | Delta period | Omicron period | p-val |
---|---|---|---|---|---|---|
Immunomodulatorya | 146 | 67 | 5 | 44 | 30 | 0.39 |
Only IGIV (n = 8) | 8 (5.5) | 6 (9.0) | 0 (0.0) | 1 (2.3) | 1 (3.3) | 0.76 |
Only steroids (n = 18) | 18 (12.3) | 7 (10.4) | 1 (20.0) | 7 (15.9) | 3 (10.0) | 0.86 |
IGIV and steroids (n = 120) | 120 (82.2) | 54 (80.6) | 4 (80.0) | 36 (81.8) | 26 (86.7) | 0.71 |
First IGIV (n = 13)b | 13 (10.8) | 7 (13.0) | 1 (25.0) | 2 (5.6) | 3 (11.5) | 0.96 |
IGIV and steroids at once (n = 88)b | 88 (73.3) | 37 (68.5) | 3 (75.0) | 27 (75.0) | 21 (80.8) | 0.67 |
First steroids (n = 11)b | 11 (9.2) | 6 (11.1) | 0 (0.0) | 3 (8.3) | 2 (7.7) | 1 |
Unknown order (n = 8)b | 8 (6.7) | 4 (7.4) | 0 (0.0) | 4 (11.1) | 0 (0.0) | 0.7 |
Steroids (days of treatment), median [IQR] | 11 [4–22] | 19 [4–25] | 4 [3.5–16.5] | 6.5 [4–17] | 9 [5–13] | 1 |
Anakinra (n = 1) | 1 (0.7) | 1 (0.7) | 0 | 0 | 0 | 1 |
Adjuvant treatmentc (MIS-C cases) | 152 | 73 | 5 | 44 | 30 | 1 |
Oxygen treatment | 7 (4.6) | 5 (6.8) | 0 | 2 (4.6) | 0 | 0.83 |
ECMO | 1 (0.7) | 1 (1.4) | 0 | 0 | 0 | 1 |
IMV | 3 (2.0) | 2 (2.7) | 0 | 1 (2.3) | 0 | 1 |
NIV | 3 (2.0) | 2 (2.7) | 0 | 1 (2.3) | 0 | 1 |
Hemofiltration | 2 (1.3) | 1 (1.4) | 0 | 0 | 1 (3.3) | 0.83 |
Inotropic | 48 (31.6) | 24 (32.9) | 0 | 14 (31.8) | 10 (33.3) | 1 |
Antibiotics | 124 (81.6) | 59 (80.8) | 5 (100) | 36 (81.8) | 24 (80.0) | 1 |
Other treatmentsd | 40 | 24 | 0 | 13 | 3 | 0.47 |
aTotal number of cases (n) refers to all the cases for which steroids, IGIV, or both of them were administered
bPercentages for subcategories refer to the number of cases receiving IGIV and/or steroids
cTotal number of cases (n) refers to all MIS-C cases included in the study
dOther treatments include: AAS (n = 29), enoxaparin (n = 11), hydroxychloroquine (n = 2), remdesivir (n = 1), insulin (n = 1), vitamin K (n = 1)